Printer Friendly

/C O R R E C T I O N -- ROBERTS PHARMACEUTICALS/

 /C O R R E C T I O N -- ROBERTS PHARMACEUTICALS/
 In NY058 -- Roberts Pharmaceuticals contract -- moved yesterday


(Thursday, June 25), we are informed by the company that the headline should be "ROBERTS PHARMACEUTICALS TO ENTER A CLINICAL TRIAL CONTRACT ON NEW DRUG FOR PROSTATE ENLARGEMENT" sted of "...FOR PROSTATE CANCER" as originally issued.
 The complete corrected release is repeated below:
 ROBERTS PHARMACEUTICALS TO ENTER A CLINICAL TRIAL CONTRACT ON
 NEW DRUG FOR PROSTATE ENLARGEMENT
 EATONTOWN, N.J., June 25 /PRNewswire/ -- In a statement made earlier today, Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced that Roberts' contract research organization subsidiary, VRG International, has entered into a contract with Yamanouchi U.K. Limited, a subsidiary of Yamanouchi Pharmaceutical Co., Ltd. of Japan for clinical trials of tamsulosin (YM617), a drug for the treatment of urinary obstruction associated with benign prostatic hypertrophy (BPH). This compound, discovered by Yamanouchi, belongs to a class of compounds known as alpha adrenergic blockers. Tamsulosin is currently entering late stage (Phase III) clinical trials in the United States and awaiting an approval from the Ministry of Health and Welfare in Japan.
 BPH is a common male urological disease affecting about 80 percent of North American men by the time they reach the age of 80. About 10 percent to 20 percent of men over 50 years old will undergo surgery to remove the excess prostate tissue and relieve the blockage. BPH is caused by an overgrowth of prostatic tissue obstructing the urinary bladder outlet. Left untreated, BPH can result in significant urinary tract problems including difficulty in bladder emptying and kidney dysfunction.
 "Tamsulosin is a therapeutic alternative to surgery," said Dr. Robert A. Vukovich, Roberts chairman and CEO. "With tamsulosin, patients with BPH may be able to delay or avoid prostatic surgery entirely."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and nonprescription pharmaceuticals in the United States and abroad.
 -0- 6/26/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: CON


GK -- NY044 -- 4241 06/26/92 13:15 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 26, 1992
Words:387
Previous Article:RHODE ISLAND $225 MIL. TAX ANTICIPATION NOTES RATED 'F-1+' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:EL PASO ELECTRIC ANNOUNCES ELECTION OF TWO NEW DIRECTORS
Topics:


Related Articles
CONVERGENT SOLUTIONS RELEASES CS/ADS 6.4 DATABASE INDEPENDENT 4GL WITH INTERFACE TO INFORMIX
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES UK APPROVAL FOR SOMAGARD
SPI PHARMACEUTICALS ANNOUNCES SECOND QUARTER DIVIDEND
IBM AND MULTI SOFT SIGN SOFTWARE MARKETING AGREEMENT
DCA ANNOUNCES SELECT COMM SERVER WITH PC ROUTER SUPPORT
IBM AND MULTI SOFT SIGN ADDITIONAL MARKETING AGREEMENT
Compuware Delivers Enhanced Enterprise Test Data Management Solution; Compuware File-AID/CS 3.0 Offers Rich Data-Management Functionality With...
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.
Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters